Recently, Elifcan et al. evaluated the relationship between the CD34+ hematopoietic progenitor cells dose and survival in MM patients who underwent auto-HCT and reported that the increase in the amount of CD34+ cells dose during HDT in MM patients shortened the platelet and neutrophil engraftment time and improved OS [10]. The gene discussed is CD34; the disease is Miyoshi myopathy.